As a prominent leader in the CDMO sector, Asymchem (Stock Code: 002821.SZ/6821.HK) has been at the forefront of providing comprehensive R&D and integrated production solutions across the pharmaceutical value chain for over 25 years. Building on a strong foundation in small molecule CDMO services, we have expanded our expertise to encompass peptides, oligonucleotides, biologics, drug product, and clinical research services.
Our business model continues to evolve through technology transfer initiatives, with a strategic focus on continuous flow production and synthetic biology. With state-of-the-art R&D and manufacturing facilities strategically located in key regions such as China, the United States, and the United Kingdom, our global footprint reflects our commitment to excellence. With a dedicated workforce of over 9,000 professionals— 45% of whom are exclusively focused on R&D — we proudly partner with leading pharmaceutical and biotech companies worldwide.
Asymchem Limited, situated in the heart of Discovery Park in Sandwich, Kent, is our European headquarters, officially opened in 2024. This state-of-the-art facility, formerly occupied by a major pharmaceutical company, is dedicated to small molecule research, development and cGMP manufacturing. Its capabilities span hydrogenation, low-temperature chemistry, process safety testing, analytical development, and, in the near future, biotransformation and continuous flow chemistry.
Our Sandwich High-Throughput Experimentation (HTE) group is pushing the boundaries of process enabling and commercial route process design utilizing cutting-edge automation and robotics. Engineering sciences, digital tools, and advanced data analytics ensure rapid route design, robust process optimization, and scalable production—delivering both speed and quality to clients.
Our team brings together an exceptional group of scientists and engineers, with an average of 21 years of industry experience. They are known for their depth of expertise in all stages of development through to commercialization , as well as their seamless execution of technology transfer.. Leveraging advanced technologies, our laboratories and pilot plant offer clients comprehensive small molecule development and cGMP manufacturing solutions, making us your trusted partner for innovation, delivery and value.
Sandwich Core Capabilities:
- Early Development: Rapid chemistry enabling, redesign and scale-up (g – kg scale)
- Mid to Late Development & Commercialisation: New, more sustainable route scouting, design and scale-up (5 – 100s kg) with accompanying sustainability metrics
- High-Throughput Experimentation: Transformations, reaction conditions, solvent screening,
- Solid form screening: solubility, salt formation, form screening, characterisation (TGA, PXRD, DVS)
- Data-Driven Process Design: Rapid optimisation, delivering cost-effective, robust commercial processes
- Process Safety: Industry leading process safety expertise with full range of safety testing
- Analytical development: Method development & validation, structure elucidation, PAT, forced degradation, accelerated stability & elemental risk assessments and testing
- Quality Control: GMP release and stability testing of APIs, starting materials & intermediates
- Regulatory filings: Robust, phase appropriate control strategies & regulatory authoring support
- Tech transfer: Right-first-time to pilot plant and 3rd party manufacturing facilities
In 2025, the Sandwich site will capitalize on Asymchem’s industry-leading flow chemistry and biotransformation technologies by investing in advanced R&D flow chemistry equipment and high-throughput biotransformation screening. Following this, we will enhance our cGMP manufacturing capabilities with investments in flow chemistry equipment.
Additionally, we are exploring opportunities to manufacture small to medium-volume commercial APIs at our pilot plant, which will strengthen our existing clinical API supply capabilities. Operating in full compliance with rigorous cGMP and EHS regulations, we address client needs by offering high-quality and cost-effective solutions that expedite clinical trial timelines and deliver customized strategies to meet the diverse requirements of the global landscape of drug development.
By combining Asymchem’s global strengths with the local expertise and innovative culture of the Sandwich team, we are well-positioned to deliver accelerated, cost-effective, and sustainable pharmaceutical solutions. Looking ahead, we plan to expand our offerings to include both R&D and manufacturing services for peptides, oligonucleotides, and other innovative modalities!
